The company announces the submission of a 510(k) premarket notification application for its investigational inhaled nitric oxide delivery system for its INOmax gas product.
As part of its efforts to reach a global settlement to resolve opioid claims, Mallinckrodt will file for Chapter 11 bankruptcy for its specialty generics subsidiary.
Johnson & Johnson reaches $20m settlement with two US counties on lawsuits regarding the opioid crisis, exits the upcoming federal trial involving several drug manufacturers.
Purdue reaches agreement to settle opioid litigation it is facing in the US by pursuing bankruptcy and providing a suggested $10bn towards the opioid crisis.
Mallinckrodt announces a settlement agreement on a lawsuit included in the first federal trial over the opioid crisis, shortly after reaching a deal on a previous investigation.
Mallinckrodt states that its specialty branded portfolio will be named Sonorant Therapeutics and, in a U-turn, this side of the business will take Amitiza with it.
